These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 15493412)
21. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. Angiolillo DJ; Suryadevara S; Capranzano P; Zenni MZ; Guzman LA; Bass TA Catheter Cardiovasc Interv; 2009 Jan; 73(1):1-14. PubMed ID: 19089929 [TBL] [Abstract][Full Text] [Related]
22. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956 [TBL] [Abstract][Full Text] [Related]
23. [Acute coronary syndrome, stroke, arterial occlusive disease. Bring the patients out of the danger zone!]. Füessl HS MMW Fortschr Med; 2004; 146 Suppl 1():3. PubMed ID: 15493407 [No Abstract] [Full Text] [Related]
24. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone. Rothberg M Ann Intern Med; 2005 Sep; 143(6):464; author reply 464-5. PubMed ID: 16172448 [No Abstract] [Full Text] [Related]
25. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone. Eriksson P Ann Intern Med; 2005 Sep; 143(6):464; author reply 464-5. PubMed ID: 16172447 [No Abstract] [Full Text] [Related]
26. [Secondary prevention after ischemic stroke. High risk patients need special protection]. MMW Fortschr Med; 2004; 146 Suppl 1():10-1. PubMed ID: 15493413 [No Abstract] [Full Text] [Related]
27. [Recommendations for peri-procedural thrombocyte aggregation inhibition]. Sauer H; Leschke M Dtsch Med Wochenschr; 2006 Feb; 131(8):400-2. PubMed ID: 16479474 [No Abstract] [Full Text] [Related]
29. Building evidence for early initiation of clopidogrel loading in non-ST-segment elevation acute coronary syndromes: going past the American College of Cardiology/American Heart Association guidelines. Aghababian RV Ann Emerg Med; 2004 May; 43(5):666-8; author reply 668-9. PubMed ID: 15259150 [No Abstract] [Full Text] [Related]
30. The role of platelets and platelet inhibition in acute myocardial infarction. Valettas N; Herrmann HC Coron Artery Dis; 2003 Aug; 14(5):357-63. PubMed ID: 12878900 [No Abstract] [Full Text] [Related]
31. Guideline-based discharge therapy for unstable angina pectoris/non-ST elevation myocardial infarction. Richard Conti C Clin Cardiol; 2007 Oct; 30(10):489-90. PubMed ID: 17929281 [No Abstract] [Full Text] [Related]
32. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Toth PP Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814 [TBL] [Abstract][Full Text] [Related]
33. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel. van Werkum JW; Topcu Y; Postma S; Kelder JC; Hackeng CM; ten Berg JM; Verheugt FW Thromb Haemost; 2008 Mar; 99(3):637-9. PubMed ID: 18327417 [No Abstract] [Full Text] [Related]
37. Facts and controversies of aspirin and clopidogrel therapy. Faxon DP; Freedman JE Am Heart J; 2009 Mar; 157(3):412-22. PubMed ID: 19249409 [TBL] [Abstract][Full Text] [Related]
38. The clinical importance of laboratory-defined aspirin resistance in patients presenting with non-ST elevation acute coronary syndromes. Acikel S; Yildirir A; Aydinalp A; Bal U; Kaynar G; Ozin B; Muderrisoglu H Blood Coagul Fibrinolysis; 2009 Sep; 20(6):427-32. PubMed ID: 19542882 [TBL] [Abstract][Full Text] [Related]
39. [Platelet inhibition remains the second choice. "Anticoagulation should always be the goal" (interview by Dr. med. Jochen Aumiller)]. Connolly S MMW Fortschr Med; 2009 Apr; 151(16):11. PubMed ID: 19658287 [No Abstract] [Full Text] [Related]
40. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention. Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]